| Stereochemistry | ACHIRAL |
| Molecular Formula | C13H11ClN2O2 |
| Molecular Weight | 262.692 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(NC2=C(C=CC=N2)C(O)=O)C=CC=C1Cl
InChI
InChIKey=CLOMYZFHNHFSIQ-UHFFFAOYSA-N
InChI=1S/C13H11ClN2O2/c1-8-10(14)5-2-6-11(8)16-12-9(13(17)18)4-3-7-15-12/h2-7H,1H3,(H,15,16)(H,17,18)
| Molecular Formula | C13H11ClN2O2 |
| Molecular Weight | 262.692 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Clonixin is a nonsteroidal agent. It is an anilino-nicotinic acid derivative. It is a drug of anti-inflammatory antipyretic and analgesic activity that produces minor digestive side-effects. At high concentrations, clonixin inhibited PGE2 formed by COX-2 and partly by COX-1 activity. The drug is indicated for the relief of headaches, muscle aches, joint, dental, ear, dysmenorrhea, post-traumatic, post-surgical, gynecological. Adverse effects are occasionally nausea, dizziness, and somnolence, were mild and transient. On rare occasions, and administering high doses, it is possible the appearance of dry mouth or constipation. Concomitant use of anticholinergic drugs to be avoided by the possibility that they enhance their effects atropine.
Originator
Approval Year
Doses
AEs
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
Drug as perpetrator
Drug as victim
Tox targets
PubMed
Patents
Sample Use Guides
clonixin (Clx) between 1 x 10(-6) M and 3 x 10(-4) M, decreases the overshoot (OS), action potential amplitude (APA), Vmax and frequency of primary and subsidiary cells, however pacemaker cells differ in their sensitivity to Clx. At 2 x 10(-6) M, Clx completely blocked the spontaneous beating of primary cells.
